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Summary
Human low-grade gliomas represent a population of brain tumors that remain a therapeutic challenge. Preclini-
cal evaluation of agents, to test their preventive or therapeutic efficacy in these tumors, requires the use of animal
models. Spontaneous gliomas develop in models of chemically induced carcinogenesis, such as in the transplacental
N-ethyl-N-nitrosourea (ENU) rat model. However, without the ability to detect initial tumor formation, multiplic-
ity or to measure growth rates, it is difficult to test compounds for their interventional or preventional capabilities.
In this study Fisher-334 rats, treated transplacentally with ENU, underwent magnetic resonance imaging (MRI)
examination in order to evaluate this approach for detection of tumor formation and growth. ENU-induced intracra-
nial cerebral tumors were first observable in T2-weighted images beginning at 4 months of age and grew with a
mean doubling time of 0.487 ± 0.112 months. These tumors were found histologically to be predominately mixed
gliomas. Two therapeutic interventions were evaluated using MRI, vitamin A (all-trans retinol palmitate, RP), as
a chemopreventative agent and the anti-angiogenic drug SU-5416. RP was found to significantly delay the time to
first tumor observation by one month (P = 0.05). No differences in rates of tumor formation or growth rates were
observed between control and RP-treated groups. MRI studies of rats treated with SU-5416 resulted in reduction
in tumor growth rates compared to matched controls. These results show that MRI can be used to provide novel
information relating to the therapeutic efficacy of agents against the ENU-induced tumor model.
Introduction
Gliomas comprise the majority of the primary brain
tumors diagnosed annually in the United States [1,2].
Of these tumors, low-grade gliomas are relatively
common, with low-grade astrocytic tumors alone
comprising as much as 15–32% of surgically treated
brain tumor [3,4]. These tumors are characterized as
having a benign histologic picture, indolent growth,
and prolonged survival, but their biologic behavior
is unpredictable [5–8]. Some lesions appear curable,
but low-grade tumors have been shown to have a
propensity to develop anaplastic features [5,7,9,10].
This progression is thought to be due to the genetic
instability of the low-grade gliomas, which allows
additional genetic deletions, amplifications, and muta-
tional events to occur [11]. This progression or change
in tumor grade, can take the life of the patient some-
times decades after initial diagnosis [6,12].
Currently, therapies for low-grade gliomas include
observation, resection, radiation, and chemotherapy.
Due to the infiltrative nature of gliomas, surgery is
rarely curative. In some locations, radical surgery with
newer image-guided techniques and functional map-
ping offers the prospect of prolonged survival by allow-
ing better and more complete surgical excisions. There
is controversy about the role of radiation therapy in the
management of low-grade gliomas. Some centers have
reported no benefit in length or quality of life, while oth-
ers have detected a small benefit to radiation [13–15].
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Chemotherapy regimens, found to have benefit in high-
grade gliomas, are currently in trial for low-grade
gliomas. Although there is increasing evidence that
combination-agent chemotherapy such as carboplatin
and vincristine can delay progression of low grade
gliomas, long-term outcome data (10–20 year) are not
available [16].
The current lack of curative therapeutic options for
treatment of low-grade gliomas indicates that alter-
native therapies need to be considered. However, the
scarcity of suitably characterized low-grade glioma
models for preclinical testing makes the development
of new therapies more difficult. Unfortunately, human
low-grade gliomas have not been established in cul-
ture, nor is there an in vitro model of progression
from low-grade to high-grade glioma. Thus, testing of
preventative or interventional therapies targeting glial
tumor progression currently requires the additional
development of in vivo animal models.
One potential model for low-grade gliomas is the
induction of rat brain tumors with chemical car-
cinogens. These are reproducible models that have
been utilized for over 30 years. However, wide varia-
tions in tumor type, location, size, and growth kinet-
ics exemplify the complexity of these brain tumor
models. Their main strength however, has been the
spontaneous nature of the induced tumors exhibit-
ing the characteristics of progression over time from
small early neoplastic proliferations, evolving into
large malignant neoplasms. The offspring of rats given
a single intravenous dose of N-ethyl-N-nitrosourea
(ENU) later than the 13th day of gestation or during
early postnatal development, develop malignant neu-
roectodermal tumors of the central and peripheral ner-
vous systems [17,18]. This tumor incidence approaches
100% in many rat strains [19,20]. The carcinogenic
effect is presumably due to the alkylation of DNA by
ENU, which occurs rapidly due to the short half-life of
the compound. Once completed, the neoplastic trans-
formation remains indolent until a much later time. In
this model, early neoplastic proliferation is followed by
microtumors and finally visible tumors develop with
increasing signs of progression to higher grades of
malignancy as indicated by increased mitoses, vascu-
larization, and necrosis. The brain tumors induced by
this carcinogen are reported to be primarily astrocy-
tomas, oligodendrogliomas, mixed gliomas, ependy-
momas, and/or medulloblastomas [21–25]. However,
this may be somewhat dependent on the strain of rat.
Several recent reports have analyzed the pathology
of transplacentally ENU-induced tumors. Zook et al.,
found that mixed gliomas grew larger, had a shorter
latency, and were significantly more malignant than
were other gliomas [26]. Mandeville et al., [27] found
that 5 mg/kg of ENU was able to induce from 30–46%
glial tumors in Fisher-344 rat offspring. Glial tumors
(mixed gliomas and oligodendrogliomas) were the
most frequent type of tumors observed. Mixed glial
tumors were usually quite large and characterized by a
mixture of oligodendroglial cells and astrocytes.
There are a limited number of reports testing agents
for their preventive or therapeutic efficacy utilizing
chemically induced models of CNS carcinogenesis.
These studies have usually been designed as sur-
vival studies either with or without interim sacrifices
to examine tumor incidence. Alexandrov’s group in
Russia has used the ENU transplacental carcinogenesis
model to examine the preventative or interventional
effects of a variety of compounds [28–31]. They
have examined the vitamins; retinol acetate, alpha-
tocopherol acetate and thiamine chloride; the antiox-
idant sodium selenite; and an inhibitor of polyamine
biosynthesis, alpha-difluoromethylornithine (DMFO).
DMFO exerted a slight inhibitory effect on tumor inci-
dence, decreased the total CNS tumor multiplicity and
the multiplicity of peripheral nervous system tumors. It
also prolonged survival time. Retinol, tocopherol, thi-
amine, and selenite did not influence the development
of transplacentally induced tumors [28]. However, all
these studies have been hampered by the inability to
detect initial tumor formation, multiplicity, and growth
of the resulting tumors, in addition to survival of indi-
vidual animals. The large variation in the time to occur-
rence and location of the resulting occult tumors has
been a tremendous limitation of this model.
Non-invasive MR imaging has demonstrated the
capability to perform repeated measurement of tumors
derived from orthotopically implanted cell lines and
to measure changes in growth rates caused by ther-
apy [32]. Additionally, ENU-induced tumors have been
reported as imagable by magnetic resonanace imaging
(MRI) [33–36]. To date, no study has reported the effect
of any therapy on chemically induced brain tumors true
incidence or growth rates. We, therefore, investigated
the capability of repeated MRI measurements to obtain
a more accurate determination of the incidence, number
and growth rate of tumors in ENU-treated animals. We
chose to test two different therapies based upon their
different modes of action. We had previously found
vitamin A to increase survival in ENU-treated animals
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fed a diet with increased vitamin A [37]. Statistical
analysis suggested that the mechanism of action was
a delay in time to tumor formation, a chemopreventa-
tive action. Tumor growth is also dependent upon blood
supply. Vascular endothelial growth factor (VEGF), by
inducing angiogenesis, has been implicated as a major
paracrine mediator of glioma development by stimu-
lation of angiogenesis [38–40]. Inhibition of VEGF
receptor 2 (FLK-1/KDR) tyrosine kinase activity has
been shown to effectively block angiogenesis and
tumor growth of gliomas implanted in rat dorsal skin
chambers [41]. We, therefore, examined the effect of
SU-5416, a small molecule inhibitor of the VEGF
receptor FLK-1, as an interventional therapy to block
the growth of small ENU-induced tumors.
Materials and methods
Chemical induction of brain tumors
As in our previous experiment, tumors were induced by
transplacental exposure [37]. Timed-pregnant Fisher-
334 dams were injected via the lateral tail vein on the
21st day of gestation with 50 mg/kg of a 0.1 M solution
of ENU (Sigma, St Louis, MO) dissolved in citric acid:
disodium phosphate buffer (pH 6.0) immediately prior
to injection. Due to the limited diameter of the head coil
used in the MRI scanner, we wanted to ensure that the
animal’s head could be imaged at one year of age. The
Fisher-344 rat strain was chosen as this strain produces
small sized animals known to be susceptible to ENU
tumor induction [20,26,27]. Second, the animals were
exposed to ENU on day 21 of pregnancy, a time shown
to cause the greatest number of brain tumors in their
offspring [42]. The offspring were delivered naturally,
were whelped by their natural mothers, and weaned at
21 days of age.
Retinol palmitate dietary treatment
All pups (26) from three dams were randomly assigned
to control (ENU exposed) or all-trans retinol palmitate
(RP) treated ENU-exposed groups (8 females, 5 males;
13 animals/group). All animals were housed in groups
based on sex and treatment groups, and had access to
food and water ad libitum. RP-treated animals received
standard chow supplemented with 150,000 IU vitamin
A palmitate/kg (Sigma, St Louis, MO) as previously
described [37,43]. This was accomplished by stirring
standard chow (Purina 5001) in an ethanol solution of
RP for 1.5 h in the dark, during which time most of the
ethanol evaporates. Although no direct measurement
of vitamin A status of the animals was made, our pre-
vious experiment had shown that 150,000 IU of dietary
vitamin A caused a change in survival in rats. Histori-
cally, this concentration has been utilized to study the
effect of vitamin A on wound healing in rats, including
local tumor irradiation or cyclophosphamide treatment
[43]. This concentration is approximately 10 times
the basal dietary concentration of vitamin A found in
normal rat chow (approximately 15,000 IU vitamin A
and 6.4 mg β-carotene/kg) which exceeds the recom-
mended minimum daily allowance for rodents. Ani-
mals on both diets gained weight corresponding to the
normal growth curves for their strain. ENU-induced
dams and ENU-control offspring were fed standard lab
rodent chow treated with ethanol alone (ENU control
animals). Food was replaced twice a week. It was pre-
pared at one-week intervals and stored at 4 ◦C.
Animals with no reported death or autopsy, were
censored after the last known time of imaging or obser-
vation. This censoring affected survival analysis and
percentage of animals with a given tumor histology.
Magnetic resonance imaging
Monthly MRI images were obtained beginning at
2 months of age. Animals were imaged every month
(months 2–8) for the purpose of determining the
incidence, number, and growth rate of each tumor.
Animals were anesthetized with 2% isoflurane in
air during the imaging sessions. All in vivo MRI
experiments were performed on a Varian system
equipped with a 7.0 Tesla, 18.3-cm horizontal bore
magnet (300 MHz proton frequency). Each MRI ses-
sion acquired T2-weighted images through the rat
brain, which were produced using the following param-
eters: TR/TE = 3,500/60, FOV = 30 × 30 mm using
a 256 × 128 matrix; slice thickness = 0.5 mm; num-
ber of slices = 50; slice separation = 0.0 mm by
interleaving two sets of 25 slices. The 0.5-mm inter-
leaved sections routinely allowed detection of tumors
as small as 1 mm in diameter. We limited this exper-
iment to the imaging of intracranial cerebral tumors.
This eliminated leptominengeal tumors, schwanno-
mas, and several other tumor types. The most rele-
vant tumor diagnosis for the remaining tumors was
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oligodendrogliomas, astrocytomas, mixed gliomas, or
ependymomas. Tumor volume determination of the
first tumor formed from serial image slices was accom-
plished as described [32]. Tumor volumes measured
excluded any cyst volume present.
Histologic evaluation
Brains and spinal cords were dissected free from the
cranium or spine and fixed by immersion fixation in
10% buffered formalin. Spinal cord tumors were visu-
ally determined with the aid of a dissecting microscope.
To evaluate the histopathology of each MRI lesion,
a 5-µm thick paraffin-embedded section of the brain
corresponding to the MRI imaged lesion was stained
with hematoxylin and eosin. All paraffin sections were
examined by a neuropathologist (MB) blinded as to the
group and age of the lesion. Each neoplasm was diag-
nosed and graded according to the criteria described by
Zook et al. [26]. In the case of heterogeneous tumors,
tumors were graded at the highest grade observed.
Additionally, paraffin sections of the cerebral tumors
used in the measurement of tumor volume (first
intraparenchymal tumor formed in the cerebrum of
the rat) were immunostained with anti-vimentin and
anti-glial fibrillary acidic protein (GFAP) antibodies
according to supplier recommendations. The immuno-
histological examinations assisted the diagnosis of
oligodendroglioma, astrocytoma, or mixed gliomas in
the tumors.
Anti-angiogenic therapy
To test the effect of the VEGF receptor inhibitor
SU-5416 (Sugen, San Francisco, CA), tumors were
induced in rats as described above, which were ini-
tially imaged by T2-weighted MRI when the animals
were 5 months of age. Animals with tumors with
smaller than 0.35-mm diameter were randomly divided
into control and treatment groups. Treated animals
received 50 mg/kg of SU-5416 twice a week in a con-
trolled release formulation. Control animals received
the suspension diluent alone. Animals were generally
imaged twice a week utilizing T2 weighting with either
0.5 or 1 mm thick slices with a TR/TE = 3,000/60.
Tumor volumes were measured as described above.
T1-weighted images with and without gadolinium con-
trast agent were acquired in selected animals during
treatment with the SU-5614 compound as detailed in
the figure legends.
Results
Development of ENU-induced tumors
Intracranial tumors induced by transplacental induc-
tion with ENU first became visible by MRI beginning
at 4 months of age in the control animals. ENU-
induced tumors appeared as a black T2-hypointense
mass, frequently associated with a T2-hyperintense
ring (white) surrounding the mass (Figure 1). After
a period of tumor growth (generally one or two
months), alterations in the signal intensity of the T2
images were observable within many of the tumors
(Figure 2, Month 2). These alterations had the appear-
ance of a reticular network in the MRI’s, which
appear to correlate with the appearance of endothe-
lial proliferation observed in histological sections of
these tumors (Figure 3). Additional data shows these
reticular areas as developing vascular elements of
the tumors. T1-weighted imaging with gadolinium
contrast enhancement (Figures 4a,b) shows contrast
enhancement of these areas, but not of the more hypo-
intense areas, which are presumably tumor cells. Later
still was the appearance of cysts within the tumor
(Figure 2, Month 3). Cyst development is consistent
with an increase in vascular permeability, as evidenced
by increased gadolinium contrast enhancement with T1
imaging (Figure 4a). All tumors with cysts were found
to be high-grade tumors, suggesting that cyst forma-
tion is a marker of progression of tumors in this model.
These tumor masses could continue to increase in size
for several months before any neurological deficits
were observed.
Effect of dietary retinol on measurement of
time to first tumor and tumor multiplicity
Dietary RP produced a significant delay in the time to
first tumor (TTT) compared to ENU controls. Figure 5
Figure 1. Detection of ENU-induced brain tumors. Transpla-
cental ENU-induced tumors (50 mg/kg on day 21 of pregnancy)
were detected by imaging with T2-weighted MRI. Representa-
tive images of several different small early tumors, showing a low
signal intensity core mass with a hyper-intense peripheral ring.
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Figure 2. Growth of ENU-induced brain tumors. MRI images of a representative tumor over several months. Tumor masses exhibited
slow growth, characterized by slow expansion of the low signal intensity core. In addition, a number of tumors developed cysts after
several months of growth.
Figure 3. Histology of a tumor with reticular network appearance
on the MRI. H&E stain of tumor shows extensive proliferation of
the vascular endothelium, indicated by white arrows.
shows that rats ingesting 150,000 IU/kg of feed of RP
exhibited a shift in the TTT curve of approximately
1 month (Wilcoxon log rank test, P = 0.05). The effect
of RP on delaying tumor formation is transitory, with
the largest effect being observed during months 4 and
5. After this time greater than 75% of the animals in
both groups had developed their first tumor.
Taking advantage of the repeated measures within
each animal, the total number of tumors at each imag-
ing session was determined by counting tumors in each
contiguous serial slice. Figure 6a shows the average
number of tumors in surviving animals each month.
Commonly, tumor multiplicity is determined at a sin-
gle time point at animal sacrifice when the total number
of tumors is counted. Since imaging allows determina-
tion of tumor multiplicity without animal sacrifice, we
were able to determine tumor multiplicity monthly for
each animal. We also determined the rate of new tumor
formation from the time of first tumor occurrence.
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Figure 4. T1-weighted MRI of tumor vasculature and cyst.
T1-weighted images were acquired (TR/TE = 750/30) without
contrast (upper panels of A & B). 2 ml of 25 mM gadolinium con-
trast agent (Magnavist) were given via an I.P. catheter and a series
of images collected over the next half-hour. Lower panels of A and
B were collect 20 min after contrast injection. SU-treated tumor
has much lower amounts of contrast enhancement suggesting less
vascular permeablity.
Shown in Figure 6b, the rate of formation of the new
tumors was analyzed using a generalized linear mixed
model. The number of new tumors in each month is
assumed to follow a Poisson distribution, based on an
analysis of the residuals. A logarithmic link is used to
relate the mean of this Poisson to a quadratic function
of time for each treatment. The plot in Figure 6b shows
the mean estimated rate of tumor formation for each
treatment arm as a function of time from formation
of the first tumor. The difference in the linear compo-
nent of the rate of tumor formation between the ENU
control group and RP treated animals was not signifi-
cantly different (P = 0.89). There is some suggestion
that the non-linear component of the rate of new tumor
formation (i.e. the curve of the line) may be different
between treatments (P = 0.04). However, there is lim-
ited data for RP treated animals having tumors for 4
months or longer that may influence the estimation of
the curvature. Thus, RP appears to delay the time to
Figure 5. Retinol delays time to first tumor. Dietary retinol palmi-
tate (150,000 lU/kg of chow) significantly delayed the appearance
of the initial MR imagable tumor by approximately one month
(Wilcoxon log rank test, P = 0.05). Tumors were detected on
contiguous 0.5-mm thick sections.
occurrence for multiple tumors, but the rate of forma-
tion is unchanged.
Effect of dietary retinol palmitate on
tumor growth rates
Using repeated MRI measurements, we were able to
quantify changes in tumor volumes over time. Figure 7
shows the changes in the first tumor volumes for ani-
mals in which the first apparent tumor was within
the cerebrum, a location that is generally consistent
with mixed glioma histology. Tumor growth rates
showed mean doubling times of 0.487 ± 0.112 and
0.559 ± 0.153 months for ENU and ENU+RP treat-
ments, respectively, a non-significant difference.
Tumor histology
A neuropathologist (MB) graded the tumors as low to
high grades of malignancy using the criteria described
by Zook et al. [26]. In the case of heterogeneous
tumors, they were graded at the highest grade observed.
Tumor histology of all tumors found at the end of
the animal’s life showed a mixture of low- to high-
grades (Table 1), consistent with previous observa-
tions in this brain tumor model. There appeared to be
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Figure 6. Detection of tumor multiplicity. The number of tumors
in each animal brain was determined at each imaging session.
Panel (A). The mean number of tumors per tumor bearing
animal ± SD. Panel (B). The rate of formation of the new tumors
analyzed using a generalized linear mixed model. The number of
new tumors in each month is assumed to follow a Poisson dis-
tribution. A logarithmic link is used to relate the mean of this
Poisson to a quadratic function of time for each treatment. The
plot shows the mean estimated rate for each treatment arm as a
function of time from formation of the first tumor for each animal.
No significant difference was detected.
a large dichotomy in the tumor grading. Tumors that
had progressed beyond the low-grade criteria had vari-
able regions of high-grade morphology, thus there were
no ‘pure’ intermediate grade tumors. Several of the
Figure 7. Measurement of tumor growth rates. Tumor volumes
were quantified for animals in which the first tumor was found
intracortically. Growth rates were determined for both control (A)
and RP-treated (B) animals. The plots show the changes in tumor
volume over time, with the curves shifted to adjust the intercepts
of the curves to be normalized to 1 mm3.
Table 1. ENU histopathological tumor grading
Low grade High grade Total
ENU control 9 26 35
Retinol palmitate 10 28 38
Tumors were identified and graded in paraffin sections
obtained from blocks containing the MRI identified
tumors. Microscopic as well as macroscopic tumors are
included in the table. No differences were found in either
the number or ratios of tumor grades.
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low-grade tumors were microtumors, which were not
imaged by MRI.
Of the tumors that were quantified for growth
rates described above, with the exception of one low-
grade oligodendroglioma, all were high-grade mixed
gliomas. These showed increased mitotic figures,
approximately 50% with marked nuclear pleomor-
phism, and approximately 20% with undifferentiated
small cell clones. High-grade tumors showed necro-
sis, marked endothelial proliferation and individual cell
necrosis. Many tumors also appeared to have entrapped
neurons as a part of the neoplasm. The mixed-gliomas
displayed a variable proportion of oligodendrocytes to
astrocytes as determined from immuno-histochemistry
(Figure 8).
Effect of dietary RP on survival
Although RP delayed time to first tumor formation
(TTT), in this experiment dietary RP did not produce a
survival advantage. Figure 9 shows the Kaplan-Meier
survival curve for the two groups. Dietary supplemen-
tation of RP although suggestive, did not increase sur-
vival significantly over the ENU control group (P =
0.18, Wilcoxon test). Early increased survival by RP
did not extend indefinitely as the survival curves merge
towards the end of the experiment at 11–12 months.
However, RP-treated animals developed a larger num-
ber of spinal cord tumors causing hind leg paralysis,
these were confirmed at autopsy (6/12 animals with
RP treatment vs. 3/12 animals for controls). The devel-
opment of spinal cord tumors or other additional sec-
ondary tumors with increasing age may have altered
the survival analysis.
Effect of anti-angiogenic therapy on
tumor growth rates
We treated rats with small ENU induced tumors, in a
second experiment, to examine the therapeutic poten-
tial for the anti-angiogenic drug SU-5416 in this model.
Changes in tumor volumes for control (n = 3) and
SU-5416 treated animals (n = 3) were determined at
4–7 day intervals (Figure 10). Tumor growth in con-
trol animals was as described above in the RP exper-
iment, with two of the three animals developing cysts
within one of their tumors and subsequently sacrificed
due to neurological impairment (Figure 10 upper left
panel and Figure 11). Treatment with the drug SU-5416
resulted in reduced growth rates of tumors in two of
three treated animals (Figure 10 lower left and right
panel and Figure 11) and possibly complete regression
of a small tumor in the third (see the discussion sec-
tion). MR images of the treated tumors showed little
change in either size or imaging characteristics such as
the development of, or increased amount of the reticu-
lar formations suggestive of vascularization. One of the
three SU-5416 treated animals developed a tumor cyst
suggesting evidence that SU-5416 may not delay the
progression of these tumors. Histological analysis sup-
ports this observation (Figure 12). For example, in ani-
mal 2836 tumor growth was minimal, but the histology
of the two tumors in this animal were both classified as
high-grade mixed gliomas. These tumors lacked signif-
icant vascular proliferation and the remaining vessels
were thin walled in contrast to control animals.
Discussion
Past studies, utilizing oncogenetic or chemically
induced tumors, have been limited by their inability
to determine the precise time and location of CNS
tumor occurrence. Alternatively, survival analysis or
time to neurological impairment has been used as a
parameter in the evaluation of neurooncopreventative
agents, but this is a crude endpoint providing little infor-
mation about tumor incidence or growth. From previ-
ous studies, we recognized that testing agents for their
preventive or therapeutic efficacy in models of spon-
taneous carcinogenesis would be difficult without the
ability to detect tumor formation or growth, in addi-
tion to animal survival. As non-invasive imaging of
brain tumors is becoming more common, MRI was
used in order to obtain a more accurate determination of
the number, incidence, and growth rate of the tumors.
Initially applied to transplanted tumor animal mod-
els to measure growth, several groups have also used
it to detect tumors produced by ENU exposure MRI
[33–36].
This study confirmed the progressive growth of
ENU-induced brain tumors in this model. It is well
documented that ENU induces areas of increased pro-
liferation that form microtumors by 60–90 days of
age [44–47]. The growth of these microtumors into
macroscopic tumors occurs between 4 and 5 months
of age, which correlates with the appearance of the
lesion within the cerebrum apparent by T2-weighted
MRI. These tumors can frequently be observed as
small 0.5 mm (approximately 3-µl volume) although
it is difficult to differentiate tumors at this size from
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Figure 8. Immunohistochemistry of the ENU-induced tumors for diagnosis of tumor type. Peroxidase reaction with hematoxylin counter-
stain. Single low grade oligedendroglioma in the entire series. (A) GFAP stained, (B) Vimentin stained. GBM pattern (either as an entire
tumor or as a part of a heterogeneous tumor). (C) GFAP stained, (D) Vimentin stained. Tumor composed mostly of glial precursors
(E) GFAP stained, (F) Vimentin stained. Nuclear pleomorphism present in the majority of the tumors (G) GFAP stained, (H) Vimentin
stained. Bar = 50 µm.
Figure 12. Histology of SU-5416 treated ENU tumors. Panel (A) Gray matter low-grade oligodendroglioma (Figure 11, right panel)
margin with neoplastic satellite cells around neurons (164× magnification). (B) Low-intermediate grade oligodendroglioma (230×
magnification). (C) High-grade mixed glioma with significantly reduced and thin walled vasculature (115× magnification). (D) Higher
magnification of panel C, showing mitotic figures, nuclear pleomorphism, hemaciderin deposits and rare thin-wall blood vessels.
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large blood vessels or MRI artifacts. Tumors reaching
1-mm diameter are readily identifiable by T2 weighted
MRI. The appearance of a hyper-intense ring on the
T2 images at the periphery of the tumor suggests that
this may be an area of increased water content, possi-
bly caused by increased vascular permeability. VEGF
has been shown to be expressed very early in the brain
Figure 9. Time to death. The Kaplan-Meier survival curve for the
two groups is shown. No significant increase (Wilcoxon log rank
test, P = 0.18) in survival due to RP treatment was detected.
Figure 10. Measurement of tumor growth volumes. Tumor volumes were quantified for animals in which the tumors were found intra-
cortically for both control (A) and SU-5416-treated (B) animals. The plots show the changes in tumor volume over time beginning on the
day of treatment. Open and closed symbols indicate multiple tumors in each of the three control animals and one of the SU-5416 treated
animals.
tumors induced by ENU [48,49]. Increases in vascu-
lar permeability are thought to be associated with the
angiogenic process and this is further supported by
the size of the tumor (∼1–2 mm), which is within the
range postulated for the development of vascular ele-
ments (the angiogenic switch [50–52]). It has been
shown that both microvessel density and VEGF lev-
els are independent prognostic markers of survival in
fibrillary low- grade astrocytoma in humans [53]. This
finding led them to suggest that fibrillary diffuse low-
grade astrocytoma is composed of a spectrum of tumors
with differing propensities to undergo malignant trans-
formation that is at least partly based on their inherent
angiogenic potential. A similar scenario can be envi-
sioned for ENU-induced tumors in this model.
ENU-induced tumors were found to increase in size
throughout the animal’s life. Although tumor volume
is negatively linked with survival [26], the size of the
tumor is not a good predictor of survival, as several ani-
mals with extremely large tumors showed no neurolog-
ical deficits and survived for extended periods (data not
shown). Because of the rapid growth rate of the mixed
gliomas, we believe that the majority of tumors imaged
developed into mixed gliomas, which is supported by
the histological and immuno-cytochemical results. The
tumor growth analysis for the RP dietary treatment was
limited to the first tumor to appear within the cerebrum
by MR imaging. We observed that a majority of the
macroscopic intracranial tumors induced in the Fisher-
344 rat offspring were mixed gliomas thus suggesting a
limitation of the potential variation in histological types
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Figure 11. Growth inhibition of ENU-induced brain tumors. MRI images of representative tumors over 49 days. Control animal (upper
left panel) had bilateral tumors that exhibited rapid growth with formation of cysts at 24 days of observation. SU-5416 animals in contrast
(lower left (high-grade mixed glioma) and right panels (low-grade oligodendroglioma)) exhibited a large reduction in tumor growth rates.
SU-5416 animals developed cysts later (49 days) and in smaller tumors than controls.
of tumors induced in this strain. The mean doubling
times of 0.487±0.112 months for ENU induced tumors
is in general agreement with the 11.03 ± 7.74 days
(0.363±0.255 months) observed by Nakajima et al. in
Wistar rats [34].
We did not conduct an exhaustive search for early
neoplastic proliferations or microtumors. The use of
tumor diagnosis at the time of terminal sacrifice
describes very little of the ‘natural history’ of these
tumors and is of minimal significance except to reaffirm
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the finding that the tumors imaged were generally a
homogenous population of mixed gliomas. We believe,
based on the literature and our unpublished observa-
tions, that there is a strong correlation between the size
of a tumor and its grade. Unfortunately, due to the lim-
ited number of animals in this pilot study, we were
unable to perform interim sacrifices to correlate tumor
size with grading. However, all of the large tumors that
were imaged and graded as ‘high grade’ at sacrifice
were derived from small tumors. Low-grade tumors
were only observed as small tumors. The low num-
ber of anecdotal low-grade tumors are reflective of the
time of sacrifice (late-stage) and may not be reflective
of the tumor histology of the earlier occurring small
tumors that progressed to be high-grade, malignant
mixed gliomas.
This study, as does our previous one, supports that
in the ENU model, retinoids may delay the onset of
brain tumor formation, but do not appear to prevent
it. This observation is similar to the effect of retinoids
in delaying onset of ENU-induced leukemia in mice
[54,55]. Our observation that RP increases the latency
period for macroscopic tumors is in conflict with an ear-
lier report by Grubbs et al. [56], where retinyl acetate,
13-cis-retinoic acid and all-trans-retinoic acid did not
alter the incidence, number or latency period of the
induced tumors. However, dosage and chemical form
of the retinoid, strain of rat used and methodology used
to detect initial tumor formation varied between the two
experiments and may explain the discrepancy.
The lack of treatments with therapeutic efficacy for
brain tumors has driven the continued search for novel
therapies. Although the ENU–CNS tumor model has
been known for over 30 years, there are relatively few
reports of therapeutic trials try to inhibit the process
of tumor induction or progression in rats. Particularly
attractive are therapies that limit the growth or progres-
sion of the glioma by modulating the proliferative rate
of either the tumor or the tumor’s vasculature. Both
chemopreventative and anti-angiogenic therapies have
been proposed as methods for blocking tumor forma-
tion and growth. However, many of the chemopreventa-
tive agents are gaining recognition as potentially having
anti-angiogenic properties. As described above, VEGF
has been shown to be expressed very early in the brain
tumors induced by ENU [48,49]. All-trans retinoic acid
(RA), 13-cis RA and all-trans retinol reduced VEGF
secretion by human keratinocytes in primary cultures
[57]. Reductions were observed at concentrations as
low as 10−10 M for all-trans RA, a level that is easily
reached in vivo during retinoid treatment.
Increased cyclooxigenase (Cox) activity has also
been reported to simulate angiogenesis [58]. The abil-
ity of NSAIDs (non-selective Cox 1 and 2 inhibitors)
to exert a protective effect on the development of neu-
ral tumors [31], suggests that Cox may play a role in
brain tumor development as has been shown in colon
cancer. Retinoids (RA, 13-cis-RA, and retinol acetate)
have been shown to markedly suppress increases in
amounts of Cox-2 and the production of PGE2 stim-
ulated by phorbol myristate acetate (PMA) in human
oral epithelial cells [59]. The authors also found that
retinoids suppressed the induction of Cox-2 mRNA
by PMA. Nuclear run-offs revealed increased rates of
Cox-2 transcription after treatment with PMA; this
effect was inhibited by all-trans-RA. Transient trans-
fection experiments showed that PMA caused nearly
a 2-fold increase in Cox-2 promoter activity, an effect
that was suppressed by all-trans-RA [60]. Thus both
inhibition of tumor growth and vascularization are
potential mechanisms of action for RP in the ENU
model.
It should be pointed out that previous studies with
ENU-induced brain tumors have examined tumor inci-
dence and multiplicity with either terminal or interim
sacrifices. Sacrifices provide a ‘snapshot in time’ of
tumor status in animals, and interim sacrifices to deter-
mine tumor incidence, this dramatically increases ani-
mal group size required for statistical validity, and
requires serial histological sectioning for tumor detec-
tion. The detection of time of initial tumor formation
(macroscopic), the development of multiple tumors,
and serial measurements of growth rates have not been
previously demonstrated for individual animals. Using
the MRI approach, time-to-tumor incidence appears to
be an especially sensitive early endpoint marker. The
lack of a significant increase in the survival time by RP
in this study is perplexing, especially in light of our pre-
vious study, which did find RP to increase survival time
[37]. There are several possible explanations. First, the
number of animals used in this pilot study was small.
This limited the statistical power to determine survival
differences, which was further limited by the censoring
of animals (no reported death or autopsy) at the end of
the study. Second, this study used Fisher-344 rats while
our previous study used Sprague-Dawley rats. Both
strains are susceptible to ENU-induced tumor forma-
tion, but the results of the effectiveness of RP in increas-
ing survival may indicate a strain difference. Finally,
and potentially the most important, was the alteration
in the day of transplacental tumor induction from day
15 in the previous study to day 21 in the current study.
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Although our intention was to maximize the number
of tumors induced by ENU, we may also have unex-
pectedly altered the ratios and locations of observed
CNS tumor types. We discovered a large number of
spinal cord tumors at terminal sacrifice: 3/12 animals
in the control and 6/12 animals in the RP treated group
(each group had one animal censored from analysis
due to lack of autopsy), a more frequent observation
than in our previous study. Others have also observed
this increased frequency of spinal cord tumors result-
ing from chemical induction late in the gestation period
or postnatally [20,61,62]. The occurrence of rapidly
growing spinal cord tumors in the rat is far more lethal
due to the limited space available for tumor expansion
in the spine. Thus, the lack of increased survival by
the RP-treated animals is a complex problem, which
further illustrates the difficulty in the interpretation of
survival studies with this model.
We demonstrated the ability to measure the thera-
peutic interventional capability in the ENU model uti-
lizing the anti-angiogenic drug SU-5416 in a small pilot
study. SU-5416 has been previously shown to reduce
the growth rate of an implanted high-grade glioma cell
line [41]. In our experiment, SU-5416 inhibited tumor
growth in each of the three animals treated. Two animal
tumors were growth arrested, while a third animal’s
tumor appeared to have regressed, but we are unable
to exclude that this was an artifact of the MRI or a
large blood vessel since we were unable to obtain serial
images in time of this tumor. Although SU-5416 was
able to reduce the growth rate of tumors this com-
pound appeared to not alter the presumed progression
from lower to higher grades. Treatment with SU-5614
yielded small tumors with high-grade pathology, but
with a marked absence of endothelial proliferation.
The detection of hemaciderin with tumors treated with
SU-5614 suggests that blood had leaked out of the
vasculature during treatment. The significance of this
observation needs to be examined both experimentally
and clinically with anti-angiogenic treatments. Unfor-
tunately, using MRI we are unable to accurately define
tumor grade at the time of therapy initiation, so poten-
tially the tumors were undergoing progression prior
to therapy. Alternatively, inhibitors of angiogenesis
such as SU-5416, while affecting tumor vasculature, do
not alter the biological progression of the tumor cells
within the tumor.
In conclusion, we have demonstrated that MRI
images can provide meaningful information on tumor
incidence, multiplicity, and growth rates in a sponta-
neously occurring brain tumor model. They provide
early non-invasive endpoints, which can easily be cor-
related with the survival of the animal. The ability
to perform repeated measurements to detect tumor
occurrence and growth of the spontaneous tumors,
reduces the number of animals needed for a study.
In addition, the ENU-induced brain tumor model is a
well-characterized animal model with initial low-grade
tumors progressing to higher grades. We have demon-
strated the feasibility of utilizing this model to test for
either the chemopreventative or therapeutic efficacy of
drugs on these spontaneous developing tumors before
their progression to a high-grade tumor phenotype.
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